Gastrointestinal Drugs Advisory Committee
Committee Meeting May 31, 2012, from 8 a.m. to 4:30 p.m.
Agenda: The committee will discuss new drug application (NDA) 200–436, synthetic human secretin, sponsored by Repligen Corporation, proposed for use with magnetic resonance imaging (MRI) to improve pancreatic duct visualization for the detection of duct abnormalities to enhance clinical decision making in patients with known or suspected pancreatitis.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment